EUVIMEDEUVIMED entdecken
Open Access

Serum Proteomics of Insulin Resistance Disorders Distinguish MASLD From Lipodystrophy and Insulin Receptor Defects

Maria Mironova iD, Allison Wing iD, Brent S Abel, Maren C Podszun iD, Rebecca J Brown iD, Yaron Rotman iD

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgaf516 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Maria Mironova und 5 weiteren Autor:innen. Beteiligte Einrichtung: Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Hauptthemen laut MEDLINE: Insulin Resistance, Receptor, Insulin, Lipodystrophy, Fatty Liver. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIH Office of Dietary Supplements, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Metabolic dysfunction-associated steatotic liver disease (MASLD) is linked to obesity, metabolic syndrome, and insulin resistance (IR). In IR associated with obesity or lipodystrophy (LD), caused by missing adipose tissue, hyperinsulinemia stimulates hepatic lipogenesis, causing steatotic liver disease (SLD). In contrast, insulin receptor pathogenic variants (INSR), despite hyperinsulinemia and IR, do not promote hepatic lipogenesis and steatosis. We aimed to understand SLD pathophysiology by comparing serum proteomic signatures of MASLD, LD, and INSR.

Methods

Single-center study of fasting serum proteome using SomaScan assay in 30 LD, 29 INSR, and 16 people with MASLD. Key targets were assessed in the hepatic transcriptome of patients with MASLD (n = 19) and in HepG2 cells.

Results

Of 6412 proteins, 567 differed between at least 2 groups. The proteome profiles clearly separated INSR from the other groups, whereas MASLD and LD displayed similarity, primarily in proteins involved in metabolism, liver injury, and fibrosis. Several proteins were uniquely elevated in INSR and LD compared to MASLD, particularly Factor IX and liver-expressed antimicrobial peptide 2. Serum levels of Factor IX and liver-expressed antimicrobial peptide 2 correlated with their hepatic expression, with in vitro expression unaffected by leptin, insulin, or glucose treatment.

Conclusion

This first comparative proteomics study identified shared and unique pathways in IR disorders. MASLD and LD share features, suggesting similar drivers of liver disease progression. Key liver-derived proteins differ between MASLD, INSR, and LD because of unique disorder features. We demonstrate the utility of proteomics and rare disorder studies in interrogating pathogenesis of common disorders like MASLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Insulin ResistanceReceptor, InsulinLipodystrophyFatty LiverProteomeHumansProteomicsMaleFemaleAdultMiddle AgedDiagnosis, DifferentialHep G2 CellsNon-alcoholic Fatty Liver DiseaseAgedAntigens, CD

Stichwörter der Autor:innen

adipokinesfatty liver diseaseliver fibrosisobesity

Substanzen

Receptor, InsulinINSR protein, humanProteomeAntigens, CD

Autor:innen und Institutionen

  • Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Diabetes Endocrinology and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Division of HIV, Infectious Diseases & Global Medicine, University of California San Francisco, San Francisco, CA 94143, USA.
  • Institute of Nutritional Sciences, University of Hohenheim, 70593 Stuttgart, Germany.

ORCID-Profile: Maria Mironova, Allison Wing, Maren C Podszun, Rebecca J Brown, Yaron Rotman

Förderung

  • NIDDK NIH HHS
  • NIH Office of Dietary Supplements
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Mironova, M., Wing, A., Abel, B. S., Podszun, M. C., Brown, R. J., & Rotman, Y. (2025). Serum Proteomics of Insulin Resistance Disorders Distinguish MASLD From Lipodystrophy and Insulin Receptor Defects. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf516

Vancouver

Mironova M, Wing A, Abel BS, Podszun MC, Brown RJ, Rotman Y. Serum Proteomics of Insulin Resistance Disorders Distinguish MASLD From Lipodystrophy and Insulin Receptor Defects. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf516

BibTeX
@article{Mironova2025,
  author = {Mironova, Maria and Wing, Allison and Abel, Brent S and Podszun, Maren C and Brown, Rebecca J and Rotman, Yaron},
  title = {Serum Proteomics of Insulin Resistance Disorders Distinguish MASLD From Lipodystrophy and Insulin Receptor Defects},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgaf516}
}
Kostenlos starten →